Modified-Release Tryptamine Composition for Controlled Therapeutic Duration

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The clinical use of psychedelic tryptamines is limited by factors such as bioavailability, rapid metabolism, and potential for abuse, with traditional administration methods being impractical and variable dosing leading to unwanted side effects.

Innovation Solution

A composition combining a monoamine oxidase inhibitor (MAOI) for immediate release and a tryptamine for delayed release, formulated in a single dosage form to regulate plasma concentration and duration of action, reducing abuse potential and improving bioavailability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If psychedelic tryptamines are administered orally, then bioavailability is improved, but rapid metabolism reduces therapeutic duration and effectiveness

Engineering Contradiction:

ImprovebioavailabilityVSAvoidtherapeutic duration

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The MAOI is administered in advance before the tryptamine to pre-inhibit monoamine oxidase enzymes. This preliminary action prevents rapid metabolism of the tryptamine upon administration, thereby extending therapeutic duration while maintaining bioavailability. The timing is critical to ensure enzyme inhibition is established before tryptamine absorption begins.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The MAOI acts as an intermediary substance that modulates the metabolism of the tryptamine. By inhibiting monoamine oxidase enzymes, the MAOI serves as a protective intermediary that prevents degradation of the tryptamine, thus extending its half-life and therapeutic duration in the body.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If traditional administration methods (smoking, injection) are used, then therapeutic effect is achieved, but practicality for clinical setting is reduced

Engineering Contradiction:

Improvetherapeutic effectVSAvoidpracticality for clinical setting

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The invention replaces mechanical administration methods (smoking, injection) with an oral pharmaceutical composition. This substitution maintains therapeutic effectiveness while significantly improving ease of operation and practicality for clinical settings, as oral administration is simpler, safer, and more scalable than inhalation or injection methods.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Reliability

If repeated ingestion of ayahuasca is required, then desired effects are achieved, but patient compliance and convenience are reduced

Engineering Contradiction:

Improvedesired effectsVSAvoidpatient compliance

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The formulation is designed to provide continuous therapeutic action through controlled release mechanisms. The MAOI and tryptamine combination maintains sustained inhibition of monoamine oxidase and continuous availability of active tryptamine in the system, eliminating the need for repeated dosing while maintaining desired therapeutic effects and improving patient compliance.

Inventive Principle:

Principle #20Continuity of useful action

4Ease of manufacture

If variable dosing in traditional ayahuasca preparation is used, then preparation simplicity is maintained, but therapeutic consistency and safety are reduced

Engineering Contradiction:

Improvepreparation simplicityVSAvoiddosing consistency

Core Design Contradiction:

Ease of manufactureVSManufacturing precision

Solution Approach 1:

The invention standardizes dosing by precisely controlling the concentrations and ratios of MAOI and tryptamine in the pharmaceutical composition. This parameter control ensures consistent therapeutic dosing across all preparations, eliminating the variability inherent in traditional ayahuasca preparation while maintaining preparation simplicity through standardized manufacturing processes.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition allows for controlled and effective administration of tryptamines with improved patient compliance, reduced variability, and supervised clinical use by ensuring sustained therapeutic effects while minimizing perceptual effects.

Implementation Method 1

a monoamine oxidase inhibitor (MAOI) and a tryptamine, wherein the MAOI is formulated for immediate release and the tryptamine is formulated for delayed release

Methodology Applied

Scientific EffectMonoamine oxidase inhibition: Enzyme

Data Source

PatentUS20250339403A1Tryptamine Formulations and Uses Thereof

Publication Date: 2025.11.06 NATURAL MEDTECH PTY LTD

AI summary

The invention relates to formulations of tryptamines and monoamine oxidase inhibitors and uses thereof in methods of treatment. In particular, compositions having a modified-release of a tryptamine and an immediate release of a monoamine oxidase inhibitor. Also disclosed are methods of treating disorders with tryptamines in combination with monoamine oxidase inhibitors.